Sean Brynjelsen
Chief Executive Officer bei ETON PHARMACEUTICALS, INC.
Vermögen: 4 Mio $ am 31.03.2024
Profil
Sean E.
Brynjelsen is the President, Chief Executive Officer & Director at Eton Pharmaceuticals, Inc. He was previously the Senior Vice President-Global Business Development at Akorn, Inc. from 2015 to 2016 and the Executive Vice President-Business Development at Sagent Pharmaceuticals, Inc. from 2016 to 2017.
Brynjelsen earned an MBA from the University of Notre Dame in 2006 and completed his undergraduate and graduate degrees at the University of Illinois in 1993 and 1995, respectively.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 13.02.2024 | 1 074 940 ( 4,18% ) | 4 Mio $ | 31.03.2024 |
Aktive Positionen von Sean Brynjelsen
| Unternehmen | Position | Beginn |
|---|---|---|
| ETON PHARMACEUTICALS, INC. | Chief Executive Officer | 01.06.2017 |
Ehemalige bekannte Positionen von Sean Brynjelsen
| Unternehmen | Position | Ende |
|---|---|---|
| SAGENT PHARMACEUTICALS INC | Corporate Officer/Principal | 01.06.2017 |
| AKORN, INC. | Chief Tech/Sci/R&D Officer | 07.02.2014 |
Ausbildung von Sean Brynjelsen
| University of Notre Dame | Masters Business Admin |
| University of Illinois | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ETON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Akorn, Inc.
 Akorn, Inc. Pharmaceuticals: MajorHealth Technology Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It manufactures and markets branded and generic products including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The company was founded in 1971 and is headquartered in Lake Forest, IL. | Health Technology |
Sagent Pharmaceuticals, Inc.
 Sagent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sagent Pharmaceuticals, Inc. engages in the developing, manufacturing, and marketing of medical products. It offers injectable products such as amikacin sulfate, ampicillin and sulbactam, cefazolin, piperacillin and tazobactam, and vancomycin hydrochloride. The company was founded by Jeffrey M. Yordon in 2006 and is headquartered in Schaumburg, IL. | Health Technology |
